Effect of ABO Blood Group Incompatibility on the Outcome of Single-Unit Cord Blood Transplantation after Myeloablative Conditioning  by Konuma, Takaaki et al.
Biol Blood Marrow Transplant 20 (2014) 577e592American Society for Blood
ASBMT
and Marrow TransplantationBrief Articles
Effect of ABO Blood Group Incompatibility on the Outcome
of Single-Unit Cord Blood Transplantation after
Myeloablative Conditioning
Takaaki Konuma 1,*, Seiko Kato 1, Jun Ooi 2, Maki Oiwa-Monna 1,
Yasuhiro Ebihara 1, Shinji Mochizuki 1, Koichiro Yuji 1, Nobuhiro Ohno 1,
Toyotaka Kawamata 1, Norihide Jo 1, Kazuaki Yokoyama 1, Kaoru Uchimaru 1,
Arinobu Tojo 1, Satoshi Takahashi 1
1Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, JapanArticle history:
Received 1 November 2013
Accepted 18 December 2013
Key Words:
Cord blood transplantation
ABO incompatibility
Graft-versus-host disease
Myeloablative conditioningFinancial disclosure: See Acknowle
* Correspondence and reprint re
Hematology/Oncology, The Institu
Tokyo, 4-6-1, Shirokanedai, Minato
E-mail address: tkonuma@ims.
1083-8791/$ e see front matter 
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
ABO blood group incompatibility between donor and recipient has been associated with poor transplant
outcomes in allogeneic hematopoietic stem cell transplantation. However, its effect on the outcome of cord
blood transplantation (CBT) has yet to be clariﬁed. We retrospectively analyzed 191 adult patients who
received single-unit CBT after myeloablative conditioning for malignant disease in our institute. Major
mismatch showed a signiﬁcantly lower incidence of platelet engraftment compared with ABO match as a
reference (hazard ratio, .57; P ¼ .01). Nevertheless, there was no increase in graft-versus-host disease,
transplant-related mortality, and overall mortality after ABO-incompatible CBT. These data suggested that
donorerecipient ABO incompatibility does not have a signiﬁcant impact on outcome after myeloablative CBT
for hematological malignancies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
In contrast to solid organ transplantation, ABO blood
group incompatibility between donor and recipient is
reportedly a more common situation after allogeneic he-
matopoietic stem cell transplantation (allo-HSCT). It is well
known that ABO incompatibility of allo-HSCT can cause an
increased risk of delayed erythroid reconstitution, pure red
cell aplasia, and acute and delayed hemolysis [1,2]. However,
the association between ABO incompatibility and trans-
plantation outcomes, such as neutrophil and platelet recov-
ery, graft-versus-host disease (GVHD), and survival, is
controversial [1,2]. Moreover, most of these studies analyzed
patients receiving allo-HSCT using bone marrow or mobi-
lized peripheral blood as a stem cell source from related and
unrelated donors [1-5].
Cord blood transplantation (CBT) from an unrelated
donor is increasingly used as an alternative transplant
method for adult patients without HLA-compatible related
or unrelated donors. Althoughmost patients receive an HLA-
mismatched cord blood unit, the lower risk of GVHDwithout
compromising graft-versus-leukemia effects is one of the
most attractive advantages of CBT. We previously reported
that ABO incompatibility inﬂuenced platelet engraftment
and transfusion requirement of RBCs and platelets in CBT [6].dgments on page 580.
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13.12.563However, the effects of ABO incompatibility on GVHD and
survival after myeloablative CBT are limited. In the present
study, we analyzed the neutrophil and platelet recovery,
GVHD, transplant-related mortality (TRM), relapse, and sur-
vival in myeloablative CBT in adult patients with malignant
disease in our institute.METHODS
This retrospective study included data from 191 adult patients who
underwent unrelated ﬁrst allogeneic transplantation using single-unit
CBT at our institute between August 1998 and February 2013.
Donorerecipient ABO compatibility was categorized as follows: ABO
match in 55 patients, major mismatch in 47, minor mismatch in 58, and
bidirectional mismatch in 31. All patients received 12 Gy total body
irradiation (TBI)-based myeloablative conditioning regimens and cyclo-
sporine with or without short-term methotrexate as a GVHD prophylaxis,
and cord blood units were selected as reported previously [7,8]. The
institutional review board of the Institute of Medical Science, The Uni-
versity of Tokyo approved this study. This study was conducted in
accordance with the Declaration of Helsinki.
The primary study endpoint was overall survival (OS), deﬁned as the
time from the date of transplantation to the date of death or last contact.
Secondary endpoints were relapse, TRM, GVHD, and neutrophil and platelet
recovery. Relapse was deﬁned by morphologic evidence of disease in pe-
ripheral blood, bone marrow, or extramedullary sites. TRM was deﬁned as
death during a remission. Both acute GVHD (aGVHD) and chronic GVHD
(cGVHD) were graded according to previously published criteria [9,10]. The
incidence of aGVHD was evaluated in all engrafted patients, whereas the
incidence of cGVHD was evaluated in engrafted patients surviving more
than 100 days. Neutrophil engraftment was deﬁned as being achieved on
the ﬁrst of 3 consecutive days during which the absolute neutrophil count
was at least 0.5  109/L. Platelet engraftment was deﬁned as being achieved
on the ﬁrst of 3 days when the platelet count was higher than 50  109/L
without transfusion support.
Baseline patient and transplant characteristics were compared using the
chi-square test for categorical variables and the Kruskal-Wallis test for
continuous variables. The probability of OS was estimated according to the
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The probabilities of the others were estimated based on a cumulative inci-
dence method to accommodate competing risks. Multivariate analysis was
performed with a Cox proportional hazardmodel adjusted for OS, and a Fine
and Gray proportional hazards model for the others.
The following variables for multivariate analysis were considered: age
(<45 versus 45 years), disease status at CBT (standard risk versus high
risk), cord blood nucleated cell count (<2.5  107 versus 2.5  107/kg),
cord blood CD34 þ cell count (<1  105 versus 1  105/kg), HLA dis-
parities based on antigen level HLA-A and -B and allele level HLA-DRB1 (1
versus 2 versus 3), sex compatibility between donor and recipient (female
donor to male recipient versus other), year of CBT (1998 to 2005 versus
2006 to 2013), and ABO compatibility between donor and recipient (match
versus major mismatch versus minor mismatch versus bidirectional
mismatch). The ABO match was considered the reference group in the
multivariate analyses.
All statistical analyses were performed with EZR, a graphic user inter-
face for R 2.13.0 [11]. P< .05 was considered signiﬁcant. Analysis of data was
performed in August 2013. The median follow-up of surviving patients was
92 months (range, 5 to 181) after CBT in the entire cohort.RESULTS
The characteristics of patients and cord blood units are
shown in Table 1. There were no signiﬁcant differences
among the 4 groups, except for HLA disparities. The major
mismatch group contained a slightly higher number of HLA
disparities as compared with the minor mismatch group
(P ¼ .07) or the bidirectional mismatch group (P ¼ .08),
although these were not statistically signiﬁcant.
The probability of OS at 5 years signiﬁcantly differed
among the 4 groups in univariate analysis (P ¼ .03)
(Figure 1A). However, multivariate analysis of mortalityTable 1
Characteristics of Patients, Cord Blood Units, and Transplantation
Total Match
Number (%) 191 55 (28
Age, yr, median (range) 40 (16-55) 40 (16
Disease type, n (%)
AML 101 (52) 30 (54
ALL 45 (23) 17 (30
MDS 25 (13) 5 (9)
CML 11 (5) 1 (1)
NHL 9 (4) 2 (3)
Disease status at CBT,* n (%)
Standard risk 79 (41) 24 (44
High risk 112 (58) 31 (54
Conditioning regimen, n (%)
TBI12GyþAra-C/G-CSFþCY 131 (68) 34 (61
TBI12GyþAra-CþCY 31 (16) 9 (16
TBI12GyþCY 16 (8) 6 (10
TBI12Gyþothers 13 (6) 6 (10
GVHD prophylaxis, n (%)
Cyclosporine A þ methotrexate 188 (98) 55 (10
Cyclosporine A 3 (1) 0 (0)
Number of nucleated cells, 107/kg, median (range) 2.43 (1.32-5.69) 2.52 (1.3
Number of CD34þcells, 105/kg, median (range) .92 (.17-7.75) .88 (.28
HLA disparities,y n (%)
1 23 (12) 4 (7)
2 106 (55) 32 (58
3 57 (29) 17 (30
4 5 (2) 2 (3)
Sex compatibility, n (%)
Female donor to male recipient 58 (30) 19 (34
Other 133 (69) 36 (65
Year of CBT, n (%)
1998-2005 102 (53) 28 (50
2006-2013 89 (46) 27 (49
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia, M
non-Hodgkin lymphoma, Ara-C, cytosine arabinoside; G-CSF, granulocyte colony-s
* For disease status at CBT, patients in complete remission (CR) 1 or CR2 witho
chronic phase for CML, and CR1 or CR2 for NHL were classiﬁed as standard risk, w
y The number of HLA disparities deﬁned as low resolution for HLA-A and -B andadjusting for other variables showed no signiﬁcant differ-
ence between ABO match and major (hazard ratio [HR], 1.20;
P ¼ .62), minor (HR, .72; P ¼ .41), or bidirectional (HR, 1.76;
P ¼ .14) mismatch (Table 2). In univariate analysis, ABO in-
compatibility was not associated with cumulative incidence
of TRM (Figure 1B) or relapse (Table 2). In multivariate
analysis, a trend toward a higher incidence of TRM was
observed in the major mismatch compared with the match
group, but this was not signiﬁcant (P ¼ .05).
In univariate analysis, there was no signiﬁcant difference
in the cumulative incidence of grades II to IV aGVHD among
the 4 groups (P ¼ .91) (Figure 1C). In multivariate analysis, a
higher number (3) of HLA disparities (HR, 1.56; 95% conﬁ-
dence interval [CI], 1.05 to 2.32; P ¼ .02), a higher cord blood
CD34 þ cell count (HR, 1.51; 95% CI, 1.05 to 2.18; P ¼ .02), and
older year of CBT (HR, 1.85; 95% CI, 1.30 to 2.65; P < .01) were
associated with a higher incidence of grades II to IV aGVHD,
but ABO incompatibility was not associated with the inci-
dence of grades II to IV aGVHD (Table 2). The cumulative
incidence of grades III to IV aGVHD signiﬁcantly differed
among the 4 groups in univariate analysis (P¼ .02). However,
multivariate analysis adjusting for other variables showed no
signiﬁcant difference in the cumulative incidence of grades
III to IV aGVHD between ABO match and major (HR, 2.56;
P ¼ .19), minor (HR, .59; P ¼ .56), or bidirectional (HR, 1.46;
P ¼ .67) mismatch (Table 2). In univariate analysis, there was
no signiﬁcant difference in the cumulative incidence of
extensive cGVHD among the 4 groups (P¼ .86) (Figure 1D). In
multivariate analysis, older age (HR,1.85; 95% CI, 1.06 to 3.23;Major Mismatch Minor Mismatch Bidirectional Mismatch P
) 47 (24) 58 (30) 31 (16)
-55) 40 (16-53) 40 (16-53) 41 (18-52) .94
.61
) 24 (51) 30 (51) 17 (54)
) 10 (21) 11 (18) 7 (22)
5 (10) 10 (17) 5 (16)
4 (8) 4 (6) 2 (6)
4 (8) 3 (5) 0 (0)
.09
) 17 (36) 30 (51) 8 (25)
) 30 (64) 28 (48) 23 (74)
.36
) 33 (70) 40 (68) 24 (77)
) 11 (23) 9 (15) 2 (6)
) 1 (2) 5 (8) 4 (12)
) 2 (4) 4 (6) 1 (3)
.10
0) 47 (100) 57 (98) 29 (93)
0 (0) 1 (2) 2 (6)
2-5.50) 2.47 (1.65-4.92) 2.38 (1.51-5.69) 2.58 (1.65-5.07) .79
-3.15) .93 (.17-1.99) .91 (.28-7.75) 1.14 (.44-2.84) .20
.05
7 (14) 8 (13) 4 (12)
) 16 (34) 37 (63) 21 (67)
) 23 (48) 12 (20) 5 (16)
1 (2) 1 (1) 1 (3)
) 13 (27) 17 (29) 9 (29) .88
) 34 (72) 41 (70) 22 (70)
.58
) 22 (46) 33 (56) 19 (61)
) 25 (53) 25 (43) 12 (38)
DS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; NHL,
timulating factor; CY, cyclophosphamide.
ut poor prognostic karyotype for AML and ALL, refractory anemia for MDS,
hereas patients in all other situations were classiﬁed as high risk.
high resolution for HLA-DRB1.
Figure 1. Probability of OS (A), cumulative incidence of TRM (B), grades II to IV aGVHD (C), and extensive cGVHD (D) according to donorerecipient ABO in-
compatibility after myeloablative CBT.
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1.02 to 3.15; P ¼ .04) were associated with a higher incidence
of extensive cGVHD, but ABO incompatibility was not asso-
ciated with the incidence of extensive cGVHD (Table 2).
ABO incompatibility was not associated with cumulative
incidence of neutrophil engraftment among the 4 groups in
univariate analysis (P ¼ .73). In multivariate analysis, a lower
cord blood CD34 þ cell count (HR, .51; 95% CI, .37 to .70;
P < .001), high risk of disease status at CBT (HR, .68; 95% CI,
.50 to .93; P ¼ .01), and older year of CBT (HR, .71; 95% CI, .53
to .96; P ¼ .02) were associated with a lower incidence of
neutrophil engraftment, but ABO incompatibility was not
associated with neutrophil engraftment (Table 2). The cu-
mulative incidence of platelet recovery was not signiﬁcantly
different among the 4 groups in univariate analysis (P ¼ .30).
In multivariate analysis, major mismatch (HR, .57; P ¼ .01)
showed a signiﬁcantly lower incidence of platelet engraft-
ment when compared with ABOmatch (Table 2). In addition,
a lower cord blood CD34 þ cell count (HR, .63; 95% CI, .45 to
.88; P < .01), lower cord blood nucleated cell count (HR, .70;
95% CI, .52 to .94; P ¼ .01), and high risk of disease status at
CBT (HR, .65; 95% CI, .45 to .94; P ¼ .02) were associated with
a lower incidence of platelet engraftment.
We also analyzed the effect of major/bidirectional
mismatch group deﬁned as combined group of major and
bidirectional mismatch. However, we were unable to ﬁnd
any impact of major/bidirectional mismatch on outcomes in
multivariate analysis, except for platelet engraftment
(Supplemental Table 1).
DISCUSSION
The ABO blood group antigens consist of oligosaccharide
glycoproteins and are expressed not only in erythrocytes butalso in neutrophils, platelets, and, vascular endothelial and
epithelial cells. The ABO antigens could be immunological
targets for ABO-incompatible donor or recipient lympho-
cytes, affecting GVHD and engraftment. Many previous
studies have reported an increased risk of aGVHD after ABO-
incompatible allogeneic bone marrow transplantation from
related and unrelated donors, particularly in minor and
bidirectional mismatch [3-5]. Igarashi et al. [12] reported an
association between the anti-host isohemagglutinin pro-
duced by donor-derived B lymphocytes and the develop-
ment of aGVHD after minor and bidirectional mismatched
allogeneic bone marrow transplantation and peripheral
blood stem cell transplantation from related and unrelated
donors. These effects might be associated with ABO-
incompatible immune responses against ABO antigens in
vascular endothelial and epithelial cells of recipients. How-
ever, it has been reported that donor-derived iso-
hemagglutinin was not identiﬁed in patients after minor and
bidirectional mismatched CBT [12,13]. The higher proportion
of naïve B lymphocytes in cord blood grafts might contribute
to defective isohemagglutinin production after ABO-
incompatible CBT, which might have contributed to the low
incidence of severe GVHD even after ABO-incompatible CBT.
Therefore, the effect of ABO incompatibility on transplant
outcome might differ depending on the kinds of stem cell
sources in allo-HSCT.
Several studies have reports on associations between ABO
incompatibility and outcomes after CBT [14-19]. Romee et al.
[14] reported no impact of ABO incompatibility on aGVHD
and cGVHD in 503 CBT recipients. Berglund et al. [15] re-
ported an increased incidence of grades II to IV aGVHD in
major mismatch recipients (n ¼ 23) of CBT. Moreover,
previous studies demonstrated lower survival for major
Table 2
Univariate and Multivariate Analysis of ABO Compatibility for the Outcomes of CBT
Univariate Analysis Multivariate Analysis
Number Percent (95% CI) P HR 95% CI P
OS* At 5 yr .03
Match 55 70.2 (55.3-81.0) 1.00 Reference
Major mismatch 47 64.8 (48.0-77.3) 1.20 .57-2.50 .62
Minor mismatch 58 83.2 (70.1-90.9) .72 .33-1.57 .41
Bidirectional mismatch 31 54.6 (35.7-70.1) 1.76 .82-3.77 .14
Relapsey At 5 yr .09
Match 55 26.9 (15.6-39.6) 1.00 Reference
Major mismatch 47 15.8 (6.8-28.2) .54 .20-1.42 .21
Minor mismatch 58 14.4 (6.6-24.9) .54 .22-1.32 .18
Bidirectional mismatch 31 32.5 (16.7-49.3) 1.08 .43-2.71 .86
TRMz At 5 yr .19
Match 55 8.1 (2.5-18.1) 1.00 Reference
Major mismatch 47 22.2 (11.3-35.4) 3.19 .97-10.46 .05
Minor mismatch 58 7.9 (2.5-17.6) 1.34 .34-5.33 .67
Bidirectional mismatch 31 16.1 (5.7-31.2) 1.99 .49-8.03 .33
Grades II-IV aGVHD At 100 d .91
Match 55 58.2 (43.9-70.1) 1.00 Reference
Major mismatch 45 66.7 (50.5-78.6) 1.06 .64-1.73 .81
Minor mismatch 58 62.1 (48.1-73.3) 1.11 .68-1.80 .66
Bidirectional mismatch 31 61.3 (41.4-76.2) 1.28 .73-2.24 .37
Grades III-IV aGVHDx At 100 d .02
Match 55 5.5 (1.4-13.7) 1.00 Reference
Major mismatch 45 20.0 (9.8-32.8) 2.56 .63-10.37 .19
Minor mismatch 58 3.4 (.6-10.7) .59 .10-3.46 .56
Bidirectional mismatch 31 9.7 (2.4-23.2) 1.46 .25-8.44 .67
Extensive cGVHD At 5 yr .86
Match 49 28.6 (16.7-41.6) 1.00 Reference
Major mismatch 40 30.5 (16.9-45.3) 1.18 .56-2.47 .65
Minor mismatch 55 27.9 (16.5-40.4) 1.24 .57-2.72 .58
Bidirectional mismatch 21 38.1 (17.8-58.3) 1.56 .67-3.63 .30
Neutrophil engraftment At 60 d .73
Match 55 96.4 (83.6-99.2) 1.00 Reference
Major mismatch 47 92.6 (75.2-98.0) .82 .56-1.20 .33
Minor mismatch 58 94.8 (83.3-98.5) 1.09 .78-1.53 .59
Bidirectional mismatch 31 88.7 (64.1-96.8) 1.06 .66-1.68 .80
Platelet engraftment At 100 d .30
Match 55 88.9 (76.0-95.0) 1.00 Reference
Major mismatch 47 70.0 (53.6-81.6) .57 .36-.90 .01
Minor mismatch 58 93.1 (81.2-97.6) .92 .66-1.28 .64
Bidirectional mismatch 31 73.3 (51.5-86.4) .78 .45-1.34 .37
* HR for overall mortality. In multivariate analysis, there were no signiﬁcant variables, but there was a trend toward a higher mortality among those with a
high risk of disease status at CBT (HR, 1.60; 95% CI, .88-2.89; P ¼ .11) and female donor to male recipient (HR, 1.64; 95% CI, .94-2.85; P ¼ .07).
y In multivariate analysis, there were no signiﬁcant variables, but there was a trend toward a higher relapse among those with a high risk of disease status at
CBT (HR, 1.71; 95% CI, .85-3.44; P ¼ .13).
z In multivariate analysis, there were no signiﬁcant variables, but there was a trend toward a higher TRM among those with female donor to male recipient
(HR, 2.05; 95% CI, .87-4.81; P ¼ .09).
x In multivariate analysis, there were no signiﬁcant variables, but there was a trend toward a higher incidence of grades III-IV aGVHD among those with a
lower cord blood CD34 þ cell count (HR, 2.75; 95% CI, .84-9.00; P ¼ .09) and a high risk of disease status at CBT (HR, 3.98; 95% CI, .80-19.65; P ¼ .08).
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other studies did not [14,18,19]. However, these studies
included a relatively heterogeneous group of patients
receiving single or double CBT after reduced-intensity or
myeloablative conditioning regimen. In most of these
studies, 3 groups of ABO mismatch, namely, major, minor,
and bidirectional mismatch, were not evaluated separately.
Of note, the advantage of our study is the relatively homo-
geneous adult patient population with hematological ma-
lignancies treated with single-unit CBT after 12 Gy TBI-based
myeloablative conditioning regimens and a cyclosporine-
based GVHD prophylaxis. Moreover, 3 groups of ABO
mismatch were evaluated separately. Therefore, we were
able to determine the potential effect of ABO incompatibility
in CBT.
In conclusion, our data showed that ABO incompatibility
affected the incidences of platelet engraftment but did not
have a signiﬁcant effect on the incidence of GVHD, relapse,TRM, and OS after CBT. These results should be interpreted
with caution because this retrospective study included a
relatively small number of Japanese patients who received
single-unit CBT after 12 Gy TBI-based myeloablative
conditioning regimens for hematological malignancies.
Although these ﬁndings should be conﬁrmed in large pro-
spective studies, ABO incompatibility does not appear to
have had a signiﬁcant impact on the outcome after CBT in
our study.ACKNOWLEDGMENTS
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Allogeneic hematopoietic stem cell transplantation for patients with a hemoglobinopathy can be curative but
is limited by donor availability. Although positive results are frequently observed in those with an HLA-
matched sibling donor, use of unrelated donors has been complicated by poor engraftment, excessive
regimen-related toxicity, and graft-versus-host disease (GVHD). As a potential strategy to address these
obstacles, a pilot study was designed that incorporated both a reduced-intensity conditioning and mesen-
chymal stromal cells (MSCs). Six patients were enrolled, including 4 with high-risk sickle cell disease (SCD)
and 2 with transfusion-dependent thalassemia major. Conditioning consisted of ﬂudarabine (150 mg/m2),
melphalan (140 mg/m2), and alemtuzumab (60 mg for patients weighing > 30 kg and .9 mg/kg for patients
weighing <30 kg). Two patients received HLA 7/8 allele matched bone marrow and 4 received 4-5/6 HLA
